CLICK here to learn more of the exciting Free Workshop   Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews ..read more

 Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS High-dose frexalimab significantly reduced disease activity, demonstrating 89% reduction in new brain lesions Phase 3 trials in relapsing MS and non-relapsing secondary progressive MS currently underway Paris, February 15, 2024. The New England Journal of Medicine published results from a positive Phase 2 clinical trial demonstrating frexalimab significantly slowed disease activity in people with relapsing multiple sclerosis (MS), corresponding to 89% and 79% reduction in ..read more

 January 14, 2014 Genetic variants linked to the risk of MS were brought to Europe during a migration around 5,000 years ago, a new study finds—and they might have helped herders survive Genes that significantly increase risk of developing multiple sclerosis were introduced to northwestern Europe by herders who migrated from the east around 5,000 years ago. SayoStudio More than 1.8 million people around the world have the autoimmune disease multiple sclerosis (MS). The condition, in which a person’s immune system attacks their brain and spinal cord, is most common in nor ..read more

  MS ECHO training for rural, frontline healthcare providers.  This training was designed to better inform local providers, recognizing that many rural residents face barriers to accessing neurological care.   The sessions take place once per month, the first Wednesday of the month for an hour. Participants can attend as many sessions as they would like, all free of charge with continuing education credits provided.   For information and to register, send email to:  sward@institutephi.org  Visit our MS Learning Channel on YouTube: htt ..read more

 Risk of disability worsening nearly 3 times greater with high GFAP: Study The ongoing worsening of disability among people with primary progressive multiple sclerosis (PPMS) may be predicted by elevated blood levels of the GFAP protein, a marker of damage to star-shaped support cells in the brain and spinal cord called astrocytes, a study suggests. The risk of disability progression was nearly three times higher in PPMS patients with high GFAP levels, the data showed. Moreover, it increased to four times higher among patients who also had low levels of neurofilament light chai ..read more

  PLAYING 2023 MS Symposium (Part 1 of 5) - LIVING WELL with MS, Pain Management, Biomarkers and More 40:26 NOW PLAYING 2023 MS Symposium (Part 2 of 5) - Mental Wellness in MS - Emotions, Mood Changes and more 57:57 NOW PLAYING 2023 MS Symposium (Part 3 of 5) - Bladder and Sexual Issues in MS 53:45 NOW PLAYING 2023 MS Symposium ( Part 4 of 5 ) - Access to Care in Underserved Communities, Health Equity & more 1:13:54 NOW PLAYING 2023 MS Symposium (Part 5 of 5) - The Power of the Patient -Taking MS into your hands + much More 2:37 NOW PLAYING 11-11-23 - A ..read more

 Trial of MP101 to enroll patients with MS, other neurodegenerative diseases by Andrea Lobo, PhD | January 16, 2024 Mitochon Pharmaceuticals is launching a pilot clinical trial to evaluate MP101, its treatment candidate for improving mitochondrial function, in people with multiple sclerosis (MS) and other neurodegenerative diseases. The announcement follows the trial’s clearance by the European Medicines Agency (EMA), which enables Mitochon to begin enrolling patients with neurodegenerative conditions in the biomarker study. The Phase 1/2atrial will enro ..read more

 GAVIN GIOVANNONI - JAN 9, 2024 Dehydration is not a good way to control your bladder symptoms. Almost 30 years ago, while doing my PhD on a urine biomarker of inflammation, I noted that urinary concentration of creatinine, a muscle metabolite excreted in the urine, correlated with disability. I soon worked out that people with MS with worse disability (higher EDSS) were more likely to have bladder dysfunction and were dehydrating themselves to manage urinary frequency, urgency and nocturia. As I asked my study subjects to collect daily urine samples, it became clear that th ..read more

  Abstract Background: Neuromyelitis optica (NMO), similar to multiple sclerosis (MS), is an autoimmune disorder affecting the central nervous system. In people with central nervous system diagnoses, high-intensity gait training (HIGT) can support neuroplasticity, improving functional mobility. While low- to moderate-intensity exercise is beneficial in improving outcomes in individuals with NMO and MS, the impact of HIGT has not been thoroughly explored. This case study explores the safety and efficacy of HIGT in an individual with NMO. Methods: A 43-year-old man with NMO participated in ..read more

Lacey E. Bromley, PhD; Bianca Weinstock-Guttman, MD Int J MS Care (2023) https://doi.org/10.7224/1537-2073.2023-063 Abstract Background: Decreases in mobility, quality of life (QOL) and cognition are commonly seen in people with multiple sclerosis (MS). Physical therapy (PT) and exercise have been shown to improve many symptoms in ambulatory individuals with MS, however, evidence in nonambulatory people with MS is lacking. Dalfampridine is a US Food and Drug Administration-approved medication for MS that treats impaired ambulation by enhancing nerve conduction. To our knowledge, no study has ..read more